Page last updated: 2024-11-11

isochlorogenic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5315832
CHEBI ID143036
SCHEMBL ID1228850
MeSH IDM0443451

Synonyms (22)

Synonym
(1s,3r,4r,5r)-3-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxy-cyclohexanecarboxylic acid
nsc-407297
NSC407297 ,
534-61-2
isochlorogenic acid
CHEBI:143036
3-{[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid
STL377917
AKOS022146313
3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxy-cyclohexanecarboxylic acid
5-o-caffeoyl quinic acid
BBL028113
SCHEMBL1228850
CWVRJTMFETXNAD-DUXPYHPUSA-N
bph-1068
bdbm153327
5z-caffeoylquinic acid
3-{[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexane-1-carboxylic acid
VS-08670
5-caffeoylquinic acid/neochlorogenic acid
caffeoyl quinic acid (isomer of 832, 833, 834)
(-)-5-caffeoyl quinic acid

Research Excerpts

Effects

ExcerptReferenceRelevance
"Isochlorogenic acid (ICGA), which has medicinal value, has been discovered in various plants."( Isochlorogenic acid (ICGA): natural medicine with potentials in pharmaceutical developments.
Cao, Y; DU, HZ; Hou, XY; Jiang, H; Liu, DH; Liu, Q; Shen, Z; Wang, HN, 2020
)
2.72

Pharmacokinetics

ExcerptReferenceRelevance
" However, its pharmacokinetic properties and bioavailability remained unresolved."( Pharmacokinetics of isochlorgenic acid C in rats by HPLC-MS: Absolute bioavailability and dose proportionality.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
" The regression analysis of AUC(0-∞) and Cmax at the three doses (5, 10 and 25mgkg(-1)) indicated that the equations were y=35."( Pharmacokinetics of isochlorgenic acid C in rats by HPLC-MS: Absolute bioavailability and dose proportionality.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
" Bioavailability of IAC in rats was poor and both Cmax and AUC(0-∞) of IAC had a positive correlation with dose."( Pharmacokinetics of isochlorgenic acid C in rats by HPLC-MS: Absolute bioavailability and dose proportionality.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
" The validated method was successfully applied to pharmacokinetic study of isochlorogenic acid A in rats for the first time."( Development and Validation of a HPLC Method for Determination of Isochlorogenic Acid A in Rat Plasma and Application to Pharmacokinetic Study.
Cen, M; Cheng, X; Liang, H; Wang, S; Xiong, X; Zeng, J, 2017
)
0.92

Bioavailability

ExcerptReferenceRelevance
" However, its pharmacokinetic properties and bioavailability remained unresolved."( Pharmacokinetics of isochlorgenic acid C in rats by HPLC-MS: Absolute bioavailability and dose proportionality.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
"To determine the absolute bioavailability in rats and the dose proportionality on the pharmacokinetics of single oral dose of IAC."( Pharmacokinetics of isochlorgenic acid C in rats by HPLC-MS: Absolute bioavailability and dose proportionality.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
" Absolute bioavailability in rats was determined by comparing pharmacokinetic data after administration of single oral (5, 10 and 25mgkg(-1)) and intravenous (5mgkg(-1)) doses of IAC."( Pharmacokinetics of isochlorgenic acid C in rats by HPLC-MS: Absolute bioavailability and dose proportionality.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
"Experimental data showed that absolute oral bioavailability of IAC in rats across the doses ranged between 14."( Pharmacokinetics of isochlorgenic acid C in rats by HPLC-MS: Absolute bioavailability and dose proportionality.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
"A new HPLC-MS method was developed to determine the bioavailability and the dose proportionality of IAC."( Pharmacokinetics of isochlorgenic acid C in rats by HPLC-MS: Absolute bioavailability and dose proportionality.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
" The absolute bioavailability was calculated to be 22."( Development and Validation of a HPLC Method for Determination of Isochlorogenic Acid A in Rat Plasma and Application to Pharmacokinetic Study.
Cen, M; Cheng, X; Liang, H; Wang, S; Xiong, X; Zeng, J, 2017
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinic acidA cyclitol carboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Decaprenyl diphosphate synthaseMycobacterium tuberculosis CDC1551IC50 (µMol)2.30000.49001.39502.3000AID1801105
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1801105DPPS Inhibition (GPP based) Assay from Article 10.1111/cbdd.12463: \\A Molecular Dynamics Investigation of Mycobacterium tuberculosis Prenyl Synthases: Conformational Flexibility and Implications for Computer-aided Drug Discovery.\\2015Chemical biology & drug design, Jun, Volume: 85, Issue:6
A Molecular Dynamics Investigation of Mycobacterium tuberculosis Prenyl Synthases: Conformational Flexibility and Implications for Computer-aided Drug Discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.03)18.2507
2000's1 (3.03)29.6817
2010's23 (69.70)24.3611
2020's8 (24.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.36 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index6.51 (4.65)
Search Engine Demand Index33.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (93.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]